Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Gilead’s $100M COMPASS Initiative Shifts Course of the HIV Epidemic
Gilead Sciences is pausing to reflect on its $100 million commitment to combat the HIV/AIDS crisis in the southern United ...
Apellis Investigates Needle Issues Amid Search for Syfovre’s Side Effect Origins
Apellis, a pharmaceutical company, is zeroing in on a possible source of a rare but severe side effect associated with ...
Shingrix Maintains Perfect Score in GSK’s Shingles Vaccine Trial in China
In October of the previous year, GlaxoSmithKline (GSK) unveiled an ambitious strategy to double its presence in the Chinese market ...
Eli Lilly Sets Example for Roche with Positive Retevmo Results in Thyroid Cancer, Highlighting Feasibility of Trial
Just a few weeks ago, Roche had expressed doubts about the feasibility of a Phase 3 study involving its RET ...
Pfizer’s Abrysvo Achieves Landmark as First Maternal RSV Vaccine to Safeguard Newborns
Pfizer’s Abrysvo has achieved a groundbreaking milestone by becoming the first vaccine to safeguard newborns against respiratory syncytial virus (RSV) ...
Teva and Glenmark Agree to $255M Settlement with DOJ in Price-Fixing Case
Teva and Glenmark Pharmaceuticals, implicated in a price-fixing scheme, are facing substantial penalties and divestiture mandates after reaching a deferred ...
Medtronic’s Layoffs Earlier This Year Propel Broad-Based Revenue Growth
Medtronic Commences FY2024 with Encouraging Single-Digit Sales Growth Across Divisions Following Strategic Cost Reduction Measures Medtronic, a prominent player in ...
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
UK Injects Ā£13M into Diverse Spectrum of Manufacturing Ventures
A pioneering funding initiative in the UK is propelling innovative strides in vaccine enhancement, cutting-edge mRNA medicines, and accelerated drug ...
Agilent Pulls the Plug on $695M Resolution Cancer Companion Diagnostic Venture, 2 Years After Acquisition
Following its acquisition of Resolution Bioscience for a sum exceeding $500 million, Agilent Technologies has made the decision to close ...
Fulcrum’s Sickle Cell Disease Program Resumes as FDA Lifts 6-Month Hold
Fulcrum Therapeutics’ ambitions in the realm of sickle cell disease (SCD) have been revitalised after a six-month hiatus. The FDA ...
Aravive’s Desperate Bid for Survival: Drastic Layoffs as Company Nears Liquidation
Aravive, a biotech company, is currently facing a critical juncture as it grapples with the aftermath of a disappointing Phase ...
Ultimovacs Explores Innovative Approaches to Conclude Phase 2 Cancer Trial Amid Prolonged Anticipation for Survival Data
Ultimovacs, a Norwegian biotech company, is grappling with prolonged delays in obtaining midphase melanoma trial data, prompting the company to ...
ICU Medical to layoff 82 workers, wind down operations at Minnesota facility
In a strategic move, ICU Medical has revealed plans to permanently shut down a manufacturing facility in Minnesota, a decision ...
Hutchmed Sets Sights on Chinese Approval for Autoimmune Disorder Drug Following Phase 3 Triumph
Hutchmed, a prominent pharmaceutical player, is gearing up for a significant move as it readies to submit sovleplenib for regulatory ...
CARsgen and Moderna Join Forces to Explore Synergy Between CT041 and mRNA Cancer Vaccine
CARsgen Therapeutics has set the stage for an intriguing partnership with Moderna that’s bound to heat up the cancer therapy ...
Gilead’s Magrolimab Faces Fresh Setback as FDA Issues Partial Clinical Hold
One month after Gilead Sciences made public its decision to halt a myelodysplastic syndromes (MDS) program centered around magrolimab, the ...
LEO Pharma Set to Acquire Timber Pharmaceuticals
Timber Pharmaceuticals has exciting news to shareāthe company is set to be acquired by LEO US Holding, Inc., a wholly-owned ...
AARP Backs Justice Department Against Chamber of Commerce’s Lawsuit on Medicare Drug Price Talks
A new development has emerged in the legal battle over the Inflation Reduction Act’s (IRA) provisions on prescription drug prices. ...
Krystal Biotech Secures $100 Million in Sale of Priority Review Voucher
Krystal Biotech proudly announces the successful transaction of its Rare Pediatric Disease Priority Review Voucher (PRV), yielding an impressive $100 ...
Johnson & Johnson’s Strategic Move: Retains 9.5% Stake in Kenvue After Share-Exchange Offer
Following its share-exchange initiative aimed at reducing its stake in Kenvue, Johnson & Johnson has announced that it will maintain ...
Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges
After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...
Phathom Pharmaceuticals Boosts Erosive GERD Application with Six-Month Stability Data Submission for Vonoprazan
Phathom Pharmaceuticals, a pioneering biopharmaceutical company dedicated to groundbreaking solutions for gastrointestinal ailments, has announced a significant stride in its ...
FDA Awards Priority Review for Full Approval of Tarpeyo in Treating IgA Nephropathy
Calliditas Therapeutics, a leading pharmaceutical company, has exciting news to share. The U.S. Food and Drug Administration (FDA) has accepted ...
FDA Approves Ingrezza (valbenazine) Capsules to Treat Chorea in Huntingtonās Disease
Neurocrine Biosciences has achieved a significant milestone with the announcement of US Food and Drug Administration (FDA) approval for Ingrezza ...
Janssen’s Bispecific Antibody Tecvayli Receives European Commission Approval for Reduced Dosing Frequency
The Janssen Pharmaceutical Companies of Johnson & Johnson have proudly unveiled a significant advancement in cancer treatment. The European Commission ...
EMA Accepts Filing for Odronextamab to Address Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Regeneron Pharmaceuticals achieved a significant milestone with the European Medicines Agency (EMA) accepting the Marketing Authorization Application (MAA) for odronextamab, ...
FDA Grants Landmark Approval to Veopoz for the Treatment of Pediatric and Adult CHAPLE Disease
On August 18, 2023, Regeneron Pharmaceuticals announced a remarkable milestone. The US Food and Drug Administration (FDA) has granted approval ...
FDA Approves Eylea HD Injection 8 mg for the Treatment of Wet Age-related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy
On August 18, 2023, Regeneron Pharmaceuticals announced a groundbreaking development in the field of ophthalmology: the US Food and Drug ...
Diversifying Strategies as Vaccine Demand Shifts: COVID-19 Vaccine Manufacturers Anticipate Fall Inoculation Season
Amidst a challenging environment of declining demand for COVID-19 vaccines, producers are eagerly awaiting the upcoming fall inoculation season as ...
